chf

Nexstim Plc agrees the next steps of the NBT stroke de novo submission with the FDA

on 15/09/2016 15:56

Euroscreen completes enrolment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes

on 14/09/2016 10:48
Study evaluating ESN364, a novel, non-hormonal small-molecule drug designed to block Hot Flashes avoiding Hormone Replacement Therapy (HRT), known to increase the incidence of cancer in menopausal women.
Read more

Mainstay Medicalís ReActiv8-B Clinical Trial for treatment of Chronic Low Back Pain enrols First Subject

on 14/09/2016 10:35
Trial to gather data in support of an application for US pre-market approval (PMA)
Read more

Confo Therapeutics appoints Dr Cedric Ververken as Chief Executive Officer

on 07/09/2016 10:50

Euroscreen opens US-IND for ESN364 on three Phase II trials

on 19/07/2016 17:16